Actively Recruiting
Randomized Study of ZL-1503 Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers and Adults with Moderate to Severe Atopic Dermatitis Using Single and Multiple Dose Escalation
Led by Zai Lab (Shanghai) Co., Ltd. · Updated on 2026-11-04
84
Participants Needed
14
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a phase 11b randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of ZL-1503 in both healthy volunteers and adults with moderate to severe atopic dermatitis AD. The study aims to assess how the drug behaves in the body and its safety profile in these populations. The study is divided into two parts Part A involves single ascending doses of ZL-1503 or placebo given to healthy volunteers, while Part B involves multiple ascending doses administered to adults with moderate to severe AD. Each participant will receive either the drug or placebo according to randomized assignment to assess different dosing levels. Participants will be monitored for adverse events, serious adverse events, laboratory abnormalities, vital sign changes, and ECG changes for up to 48 weeks after the last dose. Assessments will include clinical evaluations and safety monitoring to understand the effects and tolerability of ZL-1503. The entire study period includes dosing and long-term follow-up lasting up to nearly two years.
CONDITIONS
Brief Title
A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
Research Team
Z
ZaiLab Medical Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here